Company Quarterly Earnings Update – IMP VN – 2020 Q1

Summary of the 2020 Q1 results of Imexpharm Pharma. JSC (IMP VN) 

Q1/2020 results: highlights
  • Revenue was up 11.2% y/y. Sales in pharmacies was supported by people stocking up medicines during COVID-19 period. Sales in hospitals, excluding a one-off in Q1/2019, increased strongly by 83.4% y/y thanks to sales from new GMP-EU factories. Profitability was similar as in Q1/2019: Net profit (VND41bn, +13.2% y/y) grew at a similar pace as revenue.
  • The financial position remained solid with only a modest leverage (D/E of 0.04x).
Highlight of 2020 AGM (expected date: 30 May 2020) agenda. We recommend to VOTE FOR
  • 2019 dividend of VND1,000/share, payable after the AGM
  • Bonus shares of 30%, after the AGM
  • ESOP: with a dilution factor of 3.6% and a 3-year vetting period. The last ESOP was in 2017.
  • COVID-19 impacts: raw material disruption was eased as China production normalized. GMP-EU certification for IMP4 factory will be delayed as specialists from Portugal can’t come to Vietnam for the assessment due to the travel bans.
  • Long-term industry trends remain: sales in hospitals will be driven by an increase in national health insurance coverage and a shift of usage from imported drugs to high-production quality domestic drugs.
  • We retain our last forecasts: in 2020 revenue +25.4% and net profit +22.9%; in 2021 revenue +22.5% and net profit +17.2%.

Company ratings and target prices are accessible for clients only.

If you are interested in getting full access to our paid Primary Research Materials feel free to get in touch with us at your convenience.

Our team is actively covering 50 companies in the listed Vietnamese equity space for our clients.

Featured image credit: